Mozobil 20mg / 1ml Injection
PDF Leaflet Revision Date: 12 May 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Enhances mobilisation of hematopoietic stem cells for autologous transplantation in lymphoma and multiple myeloma.
Dosage (summary)
0.24 mg/kg SC, administered 6-11 hours prior to apheresis after 4 days of G-CSF.
Onset of Action / Duration
Onset: 30-60 mins, Duration: 4-18 hours
Special Populations
- Renal impairment
- Elderly
Pregnancy & Breastfeeding
May cause fetal harm; not established in lactation.
Key Drug Interactions
- G-CSF
- Rituximab
Contraindications
- Hypersensitivity
- Pregnancy
- Lactation
Common side effects
- Diarrhoea
- Nausea
- Injection site reactions
- Fatigue
Counselling Points
- Use effective contraception during treatment
- Do not breastfeed while on treatment
- Report any abdominal pain or discomfort
Serious warnings
- Tumor cell mobilization in leukemia
- Monitor leukocyte and platelet counts
Important Disclaimer
The Mozobil 20mg / 1ml Injection professional information leaflet below is the property of Sanofi-Aventis and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
